New Delhi, Sept. 6 -- The World Health Organisation (WHO) has unveiled the updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), incorporating vital new treatments for several cancers and diabetes, particularly addressing associated conditions such as obesity.
The revised list also features medicines for cystic fibrosis, psoriasis, haemophilia, and other blood-related disorders, according to a statement here by the global body.
Among the notable additions is the triple combination therapy elexacaftor/tezacaftor/ivacaftor (ETI), aimed at cystic fibrosis management. The update includes GLP-1 receptor agonists - semaglutide, dulaglutide, and liraglutide - alongside tirzepatide, a dual G...